Month: September 2026

ROSEMONT, Ill., Sept. 30, 2026 (GLOBE NEWSWIRE) — Wintrust Financial Corporation (“Wintrust”) (Nasdaq: WTFC) today announced it will release third quarter and year-to-date 2026 earnings results after the market closes on Monday, October 19, 2026, and host a conference call on Tuesday, October 20, 2026, at 10:00 a.m. CDT. 

For individuals wanting to listen to a simultaneous audio-only web cast, this may be accessed at Webcast Link.

Individuals interested in participating in the call by addressing questions to management should register for the call at Conference Call Link to receive a dial-in number and unique PIN to access the call seamlessly. It is recommended that you join 10 minutes prior to the event start (although you may register and dial in at any time during the call).

An accompanying slide presentation will be available on the Company’s website at www.wintrust.com, Investor Relations link.

A replay of the audio-only webcast and an accompanying slide presentation will subsequently be available at www.wintrust.com, Investor Relations, News & Events, Events & Presentations link.   The text of the third quarter and year-to-date 2026 earnings release will be available at www.wintrust.com, Investor Relations, News & Events, News link.

About Wintrust

Wintrust is a financial holding company with approximately $75 billion in assets whose common stock is traded on the NASDAQ Global Select Market. Guided by its “Different Approach, Better Results” philosophy, Wintrust offers the sophisticated resources of a large bank while providing a community banking experience to each customer. Wintrust operates more than 200 retail banking locations through 16 community bank subsidiaries in the greater Chicago, southern Wisconsin, west Michigan, northwest Indiana, and southwest Florida market areas. In addition, Wintrust operates various non-bank business units, providing residential mortgage origination, wealth management, commercial and life insurance premium financing, short-term accounts receivable financing/outsourced administrative services to the temporary staffing services industry, and qualified intermediary services for tax-deferred exchanges. For more information, please visit www.wintrust.com.

Forward-Looking Information

This press release contains forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that such statements are predictions and that actual events or results may differ materially. Wintrust’s expected financial results or other plans are subject to a number of risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” and the forward-looking statement disclosure contained in Wintrust’s Annual Report on Form 10-K for the most recently ended fiscal year and in Wintrust’s subsequent Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date made and Wintrust undertakes no duty to update the information.

FOR MORE INFORMATION CONTACT:
David A. Dykstra, Vice Chairman & Chief Operating Officer
(847) 939-9000
Amy Yuhn, Executive Vice President, Communications
(847) 939-9591
Website address: www.wintrust.com

LAFOX, Ill., Sept. 30, 2026 (GLOBE NEWSWIRE) — Richardson Electronics, Ltd. (NASDAQ: RELL) plans to release its financial results for its first quarter ended August 29, 2026 after the close of business on Wednesday, October 7, 2026. The release will be distributed by GlobeNewswire and will be available on the Company’s website at www.rell.com.

On Thursday, October 8, 2026, at 9:00 a.m. Central Time, Edward J. Richardson, Chairman and Chief Executive Officer, and Robert J. Ben, Chief Financial Officer, will host a conference call to discuss the Company’s first quarter fiscal year 2027 results. A question-and-answer session will be included as part of the call’s agenda.

Participant Instructions

Participants may register for the call here. While not required, it is recommended you join 10 minutes prior to the event start. A replay of the call will be available beginning at 1:00 p.m. Central Time on October 8, 2026, for seven days. Registration instructions are also on our website at www.rell.com.

In addition, the webcast link is available here.

About Richardson Electronics, Ltd.

Richardson Electronics, Ltd. is a leading global manufacturer of engineered solutions, green energy products, power grid and microwave tubes, and related consumables; power conversion and RF and microwave components including green energy solutions; tubes for diagnostic imaging equipment; and customized display solutions.

More than 55% of our products are manufactured in LaFox, Illinois, Marlborough, Massachusetts, or Donaueschingen, Germany, or by one of our manufacturing partners throughout the world. All our partners manufacture to our strict specifications and per our Supplier Code of Conduct. We serve customers in alternative energy, healthcare, aviation, broadcast, communications, industrial, marine, medical, military, scientific, and semiconductor markets. The Company’s strategy is to provide specialized technical expertise and “engineered solutions” based on our core engineering and manufacturing capabilities. The Company provides solutions and adds value through design-in support, systems integration, prototype design and manufacturing, testing, logistics, and aftermarket technical service and repair through its global infrastructure. More information is available at www.rell.com.

Richardson Electronics’ common stock trades on the NASDAQ Global Select Market under the ticker symbol RELL.

For Details Contact:		40W267 Keslinger Road
Edward J. Richardson	Robert Ben	PO BOX 393
Chairman and CEO	EVP & CFO	LaFox, IL 60147-0393 USA
Phone: (630) 208-2320	(630) 208-2203	(630) 208-2200 | Fax: (630) 208-2550

Appointment Is Part of ACI’s Effort to Strengthen AI Readiness, Resilience, and Deployment

SAN JOSE, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — California Water Service Group (NYSE:CWT) announced today that its Chairman & Chief Executive Officer, Martin A. Kropelnicki, has joined the Alliance for Critical Infrastructure (ACI) Board of Directors.

Kropelnicki’s appointment is part of ACI’s effort to bring together leading companies in communications, energy, financial services, information technology, transportation, and water to strengthen the country’s physical and cyber resilience and address the unique and significant risks and opportunities posed by the emergence of AI.

“We are on the precipice of technological change that is unlike anything we’ve seen before, and it is essential that we work together to identify vulnerabilities, develop protective strategies, advance smart public policy, and share best practices, both within ACI and beyond to all operators of critical infrastructure in America,” Kropelnicki said. “I am pleased to serve on ACI’s Board because I am committed to contributing to efforts to keep my customers’—and our nation’s—water systems safe.”

The expansion of ACI builds upon a foundation of over a decade of private-sector national security work in collaboration with the government and serves as confirmation of the vision of ACI’s nine founding members. For more information, visit https://criticalalliance.org.

California Water Service Group is the parent company of regulated utilities Cal Water, Hawaii Water Service, New Mexico Water Service and Washington Water Service, as well as Texas Water Service (TWSC, Inc.), a utility holding company. Together, these companies provide regulated and non-regulated water and wastewater service to more than 2.2 million people in California, Hawaii, New Mexico, Washington, and Texas. Group’s common stock trades on the New York Stock Exchange under the symbol “CWT.” Additional information is available online at www.calwatergroup.com.

CONTACT: Shannon Dean, (408) 367-8243

SAN DIEGO, Sept. 30, 2026 (GLOBE NEWSWIRE) — American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its third quarter 2026 earnings in a press release to be issued after the market closes on Tuesday, October 27, 2026.

Senior management will hold a conference call for its third quarter 2026 earnings on Wednesday, October 28, 2026 at 8:00 a.m. Pacific Time (“PT”).

To access the conference call, please dial 1 (833) 816-1162 and ask to join the American Assets Trust, Inc. Conference Call.

A live audio webcast of the conference call will be available on the “Investor Relations” section of the Company’s website at www.americanassetstrust.com. A replay webcast will be available on the Company’s website approximately one hour after the conclusion of the conference call.

About American Assets Trust, Inc.

American Assets Trust, Inc. is a full service, vertically integrated and self-administered real estate investment trust, or REIT, headquartered in San Diego, California. The Company has over 55 years of experience in acquiring, improving, developing and managing premier office, retail and residential properties throughout the United States in some of the nation’s most dynamic, high-barrier-to-entry markets primarily in Southern California, Northern California, Washington, Oregon, Texas and Hawaii. The Company’s office portfolio comprises approximately 4.3 million square feet, and its retail portfolio comprises approximately 2.4 million rentable square feet. In addition, the Company owns one mixed-use property (including approximately 94,000 rentable square feet of retail space and a 369-room all-suite hotel) and 2,302 multifamily units. In 2011, the Company was formed to succeed to the real estate business of American Assets, Inc., a privately held corporation founded in 1967 and, as such, has significant experience, long-standing relationships and extensive knowledge of its core markets, submarkets and asset classes. For additional information, please visit www.americanassetstrust.com.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of the federal securities laws, which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” or “potential” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements: adverse economic or real estate developments in our markets; defaults on, early terminations of or non-renewal of leases by tenants, including significant tenants; decreased rental rates or increased vacancy rates; our failure to generate sufficient cash flows to service our outstanding indebtedness; fluctuations in interest rates and increased operating costs; our failure to obtain necessary outside financing; our inability to develop or redevelop our properties due to market conditions; investment returns from our developed properties may be less than anticipated; general economic conditions, including the impact of tariffs and other trade restrictions; the potential impact of a prolonged government shutdown; financial market fluctuations; risks that affect the general office, retail, multifamily and mixed-use environment; the competitive environment in which we operate; system failures or security incidents through cyberattacks; the impact of epidemics, pandemics, or other outbreaks of illness, disease or virus and the actions taken by government authorities and others related thereto, including the ability of our company, our properties and our tenants to operate; difficulties in identifying properties to acquire and completing acquisitions; our failure to successfully operate acquired properties and operations; risks related to joint venture arrangements; potential litigation; difficulties in completing dispositions; conflicts of interests with our officers or directors; lack or insufficient amounts of insurance; environmental uncertainties and risks related to adverse weather conditions and natural disasters; other factors affecting the real estate industry generally; limitations imposed on our business and our ability to satisfy complex rules in order for American Assets Trust, Inc. to continue to qualify as a REIT, for U.S. federal income tax purposes; and changes in governmental regulations or interpretations thereof, such as real estate and zoning laws and increases in real property tax rates and taxation of REITs. While forward-looking statements reflect the company’s good faith beliefs, assumptions and expectations, they are not guarantees of future performance. For a further discussion of these and other factors that could cause the company’s future results to differ materially from any forward-looking statements, see the section entitled “Risk Factors” in the company’s most recent annual report on Form 10-K, and other risks described in documents subsequently filed by the company from time to time with the Securities and Exchange Commission. The company disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes.

Source: American Assets Trust, Inc.

Investor Contact:

American Assets Trust

Robert F. Barton
Executive Vice President and Chief Financial Officer
858-350-2607

Leader in targeted immuno-oncology drug development 
brings three decades of academic and biopharmaceutical oncology expertise

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the appointment of David Raben, M.D., as Chief Medical Officer. Dr. Raben brings more than 30 years of experience in academic translational research, clinical care, and oncology drug development across the biopharmaceutical sector.

“David’s deep expertise in advancing innovative and targeted oncology therapies, alongside a proven track record of leading programs from early development through regulatory approval, will be important as we advance PLN-101095,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. “We look forward to David’s leadership and insight as we progress toward key trial readouts in 2027.”

Dr. Raben is a board-certified radiation oncologist and a nationally recognized clinical expert in head and neck, lung, and genitourinary cancers. Most recently, he served as Chief Medical Officer at Bicara Therapeutics. At Bicara, Dr. Raben oversaw clinical development of the company’s first-in-class lead asset, ficerafusp alfa (BCA101), across multiple indications and stages of development, and led clinical strategy for their bifunctional antibody platform. Prior to this Dr. Raben was Vice President of Global Product Development and Product General Manager for Oncology at Amgen, where he led strategy and clinical execution for the anti-DLL3 program in neuroendocrine cancers. Earlier, as Vice President and Franchise Leader for Oncology Clinical Development at Genentech, Dr. Raben oversaw late-stage precision medicine and immunotherapy programs in head and neck, skin and thoracic cancers. Before moving to industry, Dr. Raben spent more than 20 years as a professor at the University of Colorado Cancer Center, where his research combined novel biologic therapies with radiation for patients with locally advanced head and neck and lung cancers with his translational work spanning EGFR signaling, DNA damage repair, TGF-β, and checkpoint inhibition. Dr. Raben served for over 15 years on the NRG Oncology Head and Neck Cancer Steering Committee, co-founded the NRG Radiation Developmental Therapeutics Committee, and co-led the SWOG-Genitourinary (GU) Committee’s prostate cancer subcommittee. Dr. Raben earned his B.A. from Duke University and his M.D. from Bowman Gray School of Medicine at Wake Forest University and completed his residency in radiation oncology at The Johns Hopkins Hospital.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. Pliant’s lead program is PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of ICI-refractory advanced or metastatic solid tumors. PLN-101095 is being investigated in FORTIFY, a Phase 1b indication expansion trial enrolling patients with NSCLC, tumors with high tumor mutational burden or clear cell renal cell carcinoma. Pliant’s preclinical research is focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules with programs focused on delivering siRNAs to skeletal muscle cells, adipocytes, and renal cells. For additional information, please visit: www.PliantRx.com. Follow Pliant on social media at X, LinkedIn and Facebook.

Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

In connection with the commencement of Dr. Raben’s employment with the Company on September 30, 2026 (the “Grant Date”), the Company granted him non-statutory stock options to purchase an aggregate of 575,000 shares of Company common stock (the “Inducement Grant”). The Inducement Grant was granted under the Company’s 2022 Inducement Plan (the “Plan”) and is subject to the terms and conditions of the Plan. The Inducement Grant was granted as an inducement material to Dr. Raben entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grant has an exercise price per share that is equal to the closing price of the Company’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of Dr. Raben’s start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to Dr. Raben’s continued employment with the Company through the applicable vesting dates.

Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com